Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;31(2):440-6.
doi: 10.1002/jmri.22024.

Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols

Diego R Martin  1 , Saravanan K Krishnamoorthy, Bobby Kalb, Khalil N Salman, Puneet Sharma, John D Carew, Phillip A Martin, Arlene B Chapman, Gaye L Ray, Christian P Larsen, Thomas C Pearson
Affiliations

Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols

Diego R Martin et al. J Magn Reson Imaging. 2010 Feb.

Abstract

Purpose: To retrospectively determine the incidence of nephrogenic systemic fibrosis (NSF) in patients on dialysis administered either a lower dose high-relaxivity linear gadolinium-chelate, gadobenate dimeglumine (MultiHance, MH), compared to a standard dose linear gadolinium chelate, gadodiamide (Omniscan, OM).

Materials and methods: This study was Health Insurance Portability and Accountability Act (HIPAA)-compliant and Institutional Review Board (IRB)-approved. As per institution standardized contrast-enhanced magnetic resonance imaging (MRI) protocols, patients on dialysis were imaged using either MH, between 2/2007 to 9/2008, or OM between 10/2003 and 1/2007. Rates of NSF were compared using 95% score-based confidence intervals (CI). The Wilcoxon rank sum test was used to test similarity/difference between contrast doses given to each patient group.

Results: Overall, 312 patients on dialysis received OM and eight (2.6%) developed NSF (95% CI: 1.30%-4.98%). In all, 784 patients on dialysis received MH at a mean cumulative dose of 0.11 mmol/kg (0.05-0.75 mmol/kg) and no cases of NSF were identified (upper 95% confidence bound of 0.45%). The mean cumulative dose of OM was 0.16 mmol/kg (0.1-0.9 mmol/kg) for all patients and 0.28 mmol/kg (0.1-0.8 mmol/kg) for the patients with NSF. The median OM dose was greater in patients who developed NSF (P = 0.03), and was greater than the median MH dose (P < 0.005).

Conclusion: NSF incidence in at-risk patients receiving contrast-enhanced MRI can be reduced after changing contrast administration protocols that includes changing the type and dose of contrast agent.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of cumulative doses in the gadodia-mide (OM) group with NSF.
Figure 2
Figure 2
Distribution of cumulative doses by type of gadolinium agent, either gadodiamide (OM) or gadobenate dime-glumine (MH).
Figure 3
Figure 3
Incidence of NSF in patients with endstage chronic kidney disease on dialysis versus type of gadolinium agent and number of contrast-enhanced MRI exams performed, using either gadodiamide (OM) or gadobenate dimeglumine (MH). The 95% confidence limits are shown.
See this image and copyright information in PMC

References

    1. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16:2619–2621. - PMC - PubMed
    1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxedema-like cutaneous disease in renal-dialysis patients. Lancet. 2000;356:1000–1001. - PubMed
    1. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383–393. - PubMed
    1. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:785–790. - PubMed
    1. Kuo PH, Kanal E, Alfa-Abu AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647–649. - PubMed